Effect of Erythromycin on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 28, 2024

Primary Completion Date

June 18, 2024

Study Completion Date

June 18, 2024

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG

CHF6001 DPI

Single dose of CHF6001

DRUG

Erythromycin

Repeated doses of oral Erythromycin

Trial Locations (1)

MC Comac Medical Ltd., Sofia

All Listed Sponsors

lead

Chiesi Farmaceutici S.p.A.

INDUSTRY

NCT06395610 - Effect of Erythromycin on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers | Biotech Hunter | Biotech Hunter